Indication
Pmm2-CDG
2 clinical trials
3 products
Clinical trial
A Phase 2, Randomized, Open-Label, 24-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult, Adolescent, and Pediatric Participants With PMM2-CDGStatus: Recruiting, Estimated PCD: 2025-04-01
Product
GLM101Clinical trial
A Randomized, Double-blind, Placebo-controlled Study Evaluating Acetazolamide Efficacy in Ataxia in PMM2-CDGStatus: Terminated, Estimated PCD: 2024-01-24
Product
PlaceboProduct
Acetazolamide